drugset / Trial / NCT03829657
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure
RandomizedParallel-groupTriple-blindTreatment
Summary
A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure
Timeline
- Start
- 2019-02-22
- Primary completion
- 2021-11-10
- Completion
- 2021-11-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ampreloxetine | Small molecule | — | Oral |